Prommising results of the current study warrant further investigations of HDACs class IIa inhibitors in combination with conventional chemo-radiation therapies, in which PET/CT(MRI) with [18F]TFAHA of HDAC class IIa expression-activity levels in GBM may serve as a predictive biomarker of treatment response. This evidence concerns the gene HDAC9 and glioblastoma.